海特生物(300683) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥138,635,351.99, a decrease of 16.59% compared to ¥166,204,766.30 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥1,472,018.93, representing a decline of 119.14% from a profit of ¥7,690,523.54 in the previous year[5] - Total operating revenue for Q1 2023 was ¥138,635,351.99, a decrease of 16.66% from ¥166,204,766.30 in the previous period[20] - Net profit for Q1 2023 was a loss of ¥1,715,296.26, compared to a profit of ¥10,090,383.29 in the same period last year[21] - The total comprehensive income for Q1 2023 was -1,715,296.26 CNY, down from 10,090,383.29 CNY in Q1 2022[22] - The basic and diluted earnings per share for Q1 2023 were both -0.02 CNY, compared to 0.06 CNY in the previous year[22] Cash Flow - The net cash flow from operating activities improved by 50.46%, amounting to -¥20,025,031.14 compared to -¥40,422,326.86 in the same period last year[5] - Cash inflows from operating activities totaled 159,114,665.15 CNY, a decrease from 167,526,359.10 CNY in the prior year[24] - The net cash flow from operating activities was -20,025,031.14 CNY, improving from -40,422,326.86 CNY in Q1 2022[24] - Cash inflows from investment activities were 282,677,828.84 CNY, compared to 115,509,501.15 CNY in the same period last year[24] - The net cash flow from investment activities was -349,381,558.66 CNY, worsening from -50,032,485.34 CNY in Q1 2022[24] - The net cash flow from financing activities was 286,697,791.17 CNY, compared to -3,650,000.00 CNY in the previous year[24] - The ending cash and cash equivalents balance was 665,809,620.43 CNY, up from 88,220,234.04 CNY in Q1 2022[25] - The company’s cash and cash equivalents decreased by 82,668,239.85 CNY during the quarter, an improvement from a decrease of 94,104,812.20 CNY in the same period last year[25] Assets and Liabilities - Total assets increased by 11.10% to ¥3,006,675,601.06 from ¥2,706,360,990.39 at the end of the previous year[5] - Total liabilities rose to ¥384,626,658.33 from ¥371,203,811.43, an increase of 3.43%[18] - The company's inventory increased to ¥144,527,340.20 from ¥120,180,940.03, a rise of 20.19%[18] - The company's total equity increased to ¥2,622,048,942.73 from ¥2,335,157,178.96, an increase of 12.34%[18] - The company's equity attributable to shareholders rose by 12.43% to ¥2,597,506,071.64 from ¥2,310,371,030.54 at the end of the previous year[5] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,107[12] - The largest shareholder, Wuhan Sanjiangyuan Investment Development Co., Ltd., holds 30.56% of shares, totaling 40,000,000 shares[12] - Chen Ya, an overseas individual shareholder, holds 8.44% of shares, totaling 11,050,000 shares, with 8,600,000 shares under lock-up[12] - The total number of restricted shares at the beginning of the period was 9,547,250, with 225,000 shares released and 8,790,226 shares added, resulting in a total of 18,112,476 restricted shares at the end of the period[14] - The company has a significant number of shareholders involved in financing and securities trading, with Jiang Shufen holding a total of 973,200 shares[12] - The company has a total of 1,489,868 shares under lock-up for Shen Xianglong, which will be released on August 15, 2023[14] - The total number of shares held by the top ten unrestricted shareholders is 40,000,000 shares[12] - The company has a diverse shareholder base, including both domestic and foreign investors[12] - The report indicates a focus on long-term strategies with locked shares for key executives and major shareholders[14] Investment and R&D - The company reported a significant increase of 250.07% in trading financial assets, reaching ¥504,255,857.15 due to increased investment in financial products[9] - Research and development expenses increased by 50.27% to ¥1,513,568.31, indicating a focus on innovation[9] - Research and development expenses for Q1 2023 were ¥24,195,180.16, down from ¥29,760,335.70, a decrease of 18.67%[21] - The company has plans for market expansion and product development, as indicated by the involvement of various investment funds[14] Operating Costs - Total operating costs for Q1 2023 were ¥154,418,438.44, down from ¥161,615,613.80, reflecting a reduction of 4.83%[21]